The Label · The Season, Not the Day
This name holds its accumulation label.
Mira Pharmaceuticals Inc holds its Accumulation at $0.96. The statistical read favours the sellers, held for 31 days.
As held on the ledger · 2025-12-31
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 31 days |
| Price at the screen | $0.96 |
| Valuation | N/A trailing · -2.34 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.49 |
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
| Test | Figure | Limit | What it means | Status |
|---|
| Business activity |
Permissible |
Core business clean |
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. |
Pass |
| Debt load |
Excluded |
Below 33% |
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. |
Fail |
| Interest-bearing cash |
42.21% |
Below 33% |
Interest-bearing cash and securities are 42.2% of assets, above the one-third limit. |
Fail |
| Receivables |
57.21% |
Below 49% |
Money owed to the company is 57.2% of assets, above the 49% limit. |
Fail |
| Revenue purity |
Excluded |
Below 5% |
of revenue comes from non-compliant sources, over the 5% line. |
Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Business, in Plain Words
The fundamentals · plain-English read
| Forward P/E | -2.3x |
| EPS, trailing | -1.27 |
| EPS, forward | -0.41 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -184.3%not currently earning a positive return on equity |
| FCF yield | -1.06% |
| Current ratio | 82.16comfortably covers its short-term bills |
| Beta | 1.49moves a little more than the market |
| Short interest, float | 0.00% |
| 52-week range | 0.90 - 2.45 |
| Moat | NONE |
| Market cap | $40M |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MIRA trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.